Patents Assigned to The Board Institute, Inc.
-
Publication number: 20240052331Abstract: The disclosure provides fusion proteins comprising a pleckstrin homology (PH) domain and a variant of Botulinum neurotoxin E (BoNT E) protease that cleaves certain non-canonical protein targets (e.g., PTEN). Fusion proteins described in the disclosure are useful for cleaving target proteins found in a cell, that is, in an intracellular environment. Aspects of the disclosure provide methods for inhibiting PTEN amount, activity, or function in a cell or subject, the methods comprising administering to a call or subject a fusion protein described herein.Type: ApplicationFiled: December 17, 2021Publication date: February 15, 2024Applicants: The Board Institute, Inc., President and Fellows of Harvard College, Children's Medical Center CorporationInventors: David R. Liu, Travis R. Blum, Min Dong, Hao Liu
-
Publication number: 20220348590Abstract: The present disclosure describes compounds of the formula: (I), (II), (III), (IV), (V). The compounds described herein may be cyclooxygenase (COX) (e.g., cyclooxygenase 2 (COX2)) inhibitors. The compounds may be radiolabeled. The compounds (e.g., radiolabeled compounds) may be useful (e.g., as positron emission tomography (PET) imaging agents) for diagnosing a disease. The compounds may also be useful for treating or preventing a disease. The present disclosure also describes pharmaceutical compositions and kits including the compounds; and methods of using the compounds.Type: ApplicationFiled: September 10, 2020Publication date: November 3, 2022Applicants: The Board Institute, Inc., The General Hospital Corporation, Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Antoine Bigot, Agathe Fayet, Besnik Bajrami, Jacob Hooker, Michael Placzek, Beth A. Stevens, Daniel Wilton, Steven McCarroll
-
Patent number: 11092607Abstract: The present invention relates to methods for high multiplex protein or cellular constituent analysis in single cells or single isolated aggregations of cellular constituents. The methods provide for embedding cells or isolated aggregations of cellular constituents in a hydrogel mesh and labeling of cellular constituents with labeling ligands linked to a nucleic acid tag. Cellular constituents can be determined using sequencing methods.Type: GrantFiled: October 27, 2016Date of Patent: August 17, 2021Assignees: The Board Institute, Inc., Massachusetts Institute of TechnologyInventors: Jellert Gaublomme, Aviv Regev
-
Patent number: 10766872Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:Type: GrantFiled: May 31, 2017Date of Patent: September 8, 2020Assignee: The Board Institute, Inc.Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
-
Patent number: 10696986Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems, wherein the guide sequence is modified by secondary structure to increase the specificity of the CRISPR-Cas system and whereby the secondary structure can protect against exonuclease activity and allow for 5? additions to the guide sequence.Type: GrantFiled: June 12, 2017Date of Patent: June 30, 2020Assignees: THE BOARD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Omar O. Abudayyeh, James E. Dahlman, Patrick Hsu, David A. Scott
-
Patent number: 10669540Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.Type: GrantFiled: October 13, 2017Date of Patent: June 2, 2020Assignees: THE BOARD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Feng Zhang, Bernd Zetsche, Ian Slaymaker, Jonathan Gootenberg, Omar O. Abudayyeh
-
Patent number: 9499856Abstract: Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (DDR2) gene.Type: GrantFiled: May 1, 2013Date of Patent: November 22, 2016Assignees: The Board Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Matthew Meyerson, Peter Hammerman, Alexis Ramos
-
Publication number: 20160017283Abstract: The present invention features assays for co-culturing primary cells while maintaining key biological activities specific to the primary cells. The invention is based, at least in part, on the discovery that compositions and methods for primary cells in a high-throughput co-culture platform, image analysis for distinguishing cells in co-cultures and assays that are suitable for screening of agents in epithelial cells, such as hepatocytes.Type: ApplicationFiled: March 14, 2014Publication date: January 21, 2016Applicants: massachusetts Institute of Technology, The Board Institute, Inc.Inventors: Sangeeta Bhatia, Jing Shan, Anne Carpenter, David Logan, Nathan Ross
-
Patent number: 9120810Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:Type: GrantFiled: September 26, 2013Date of Patent: September 1, 2015Assignees: THE BOARD INSTITUTE, INC., PRESIDENT & FELLOWS OF HARVARD COLLEGEInventors: Mahmud Hussain, Daisuke Ito, Jason Law, Matthias Leiendecker, Ke Liu, Benito Munoz, Stuart Schreiber, Alykhan Shamji, Andrew Stern
-
Publication number: 20140273234Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.Type: ApplicationFiled: June 2, 2014Publication date: September 18, 2014Applicants: The Board Institute, Inc., Massachusetts Institute of TechnologyInventors: Feng ZHANG, Fei RAN